By Kelly Knaub ( March 4, 2016, 5:33 PM EST) -- The U.S. Patent and Trade Office, drug industry groups and intellectual property attorneys have urged the Federal Circuit to reverse a panel decision invalidating two of The Medicines Co.'s patents for the blood-thinning drug Angiomax, as the court prepares to consider questions about what constitutes an on-sale bar....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.